In addition,Figure12C shows an increase in cytotoxic T-cell activation of 1250 cells/mm3. predicted the epitopes of the cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) and evaluated their immunogenic properties. Populace coverage analysis of competent epitopes was conducted to determine the successful use of the vaccine worldwide. The epitopes were constructed into a multiepitope vaccine by using AAY linkers between the CTL epitopes and GPGPG linkers between the HTL epitopes. The tertiary structure of the multiepitope vaccine was modeled with AlphaFold and was evaluated by Prosa-web. The results of vaccine construction were analyzed for B-cell epitope prediction, molecular docking with Toll like receptor-4 (TLR4), and molecular dynamics simulation. The results of epitope prediction obtained 4 CTL epitopes and 7 HTL epitopes that are eligible for construction of multiepitope vaccines. Prediction of the physicochemical properties of multiepitope vaccines obtained good results for recombinant protein production. The conversation showed that this interaction of the multiepitope vaccine-TLR4 complex is stable based on the binding free energy value 106.5 kcal/mol. The results of the immune response simulation show that multiepitope vaccine candidates could activate the adaptive and humoral immune systems and generate long-term B-cell memory. According to these results, the development of a multiepitope vaccine with a reverse vaccinology approach is usually a breakthrough to develop potential cervical malignancy therapeutic vaccines. == 1. Introduction BMS-214662 == Cervical malignancy cases at 6.5% is ranked as the fourth malignant cancer that causes death in women worldwide.1Human papilloma computer virus (HPV) is associated with 99.7% of cervical cancer infections.2The HPV, which is spread through sexual contact, is the most common cause of cervical cancer in women, despite the fact that there are a variety of factors that can put a woman at risk for developing the disease.3Based on their carcinogenic properties, they have been classified into two groups: high-risk HPV and low-risk HPV.4The high-risk HPV types include 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68, while the low-risk HPV types include 6, 8, 11, 40, 42, 43, 44, 53, 54, 61, 72, and 73.5About 70% of cervical cancer cases are caused by HPV types 16 and 18.6Data obtained in 2015 showed that this most prevalent types of HPV in Indonesia are 16, 18, 45, and 52.7Persistent and untreated high-risk HPV infection can cause cervical intraepithelial neoplasia to develop into carcinoma.8 There are several proteins expressed by HPV including the long control region; the early region (E1, E2, E4, E5, E6, and E7 proteins); and the late region (L1 and L2 protein).9E1 is the only HPV protein that functions as an ATP-dependent DNA helicase to Goat polyclonal to IgG (H+L)(HRPO) unwind viral double-stranded DNA. Replication of viral DNA also entails the role of E2 proteins. The double-stranded DNA computer virus cannot replicate without the E1 and E2 proteins, which attach BMS-214662 to and unwind the replication origin.10For the initiation of viral DNA replication, E1 interacts with E2 to establish the starting point of replication.11Moreover, E1 is highly conserved compared to other HPV proteins, making it a stylish vaccine target.10E2 is also an attractive target for therapeutic vaccines as it is expressed at several stages of precancerous lesion development.12In addition, another study by Ren et al.showed that this E2 protein mediates an alternative pathway to carcinogenesis.13 Surgery, chemotherapy, and radiation therapy are some of the therapies available for patients who have been diagnosed with cervical malignancy.14Additionally, cervical cancer can be prevented through vaccination and periodic screening. Currently, three types of prophylactic vaccines are licensed to prevent HPV infection, namely Cervarix, Gardasil, and Gardasil 9.15The three vaccines are based on the L1 gene BMS-214662 expression. The complexity of pathogens, immune evasion systems, and mutations in a pathogen that will make the vaccine less effective are some of the difficulties that are associated with the development of novel vaccines.16The use of E1 and E2 proteins, which have enzymatic properties that make them less prone to mutation, is a potential target in the development of a novel vaccine. BMS-214662 HPV has an immune system evasion mechanism, allowing cervical cancer contamination to arise. It shows the importance of the adaptive immune response role. Antigen presenting cells (APCs) identify viral proteins via the pattern acknowledgement receptor (PRR). The protein is then processed by a transporter associated with antigen processing (TAP) into small peptides that are offered to T lymphocytes by HLA class I or II.17Therefore, the interaction between peptides and HLA is critical for the stage of antigen identification by T cells. Due to the.